DDInter602 DDInter1376
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dronedarone {u} (Compound) resembles {v} (Compound) Ibutilide
Dronedarone {u} (Compound) binds {v} (Gene) CACNA1F
Dronedarone {u} (Compound) causes {v} (Side Effect) Skin disorder
Dronedarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Dronedarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bisacodyl
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Dronedarone {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Dronedarone {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Dronedarone (Compound) resembles Ibutilide (Compound)
Dronedarone (Compound) binds CACNA1F (Gene)
Dronedarone (Compound) causes Skin disorder (Side Effect)
Dronedarone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Dronedarone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib
Dronedarone may lead to a major life threatening interaction when taken with Sorafenib